vs
Side-by-side financial comparison of Piedmont Realty Trust, Inc. (PDM) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Piedmont Realty Trust, Inc. is the larger business by last-quarter revenue ($143.3M vs $129.7M, roughly 1.1× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 0.4%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 0.0%).
Piedmont Realty Trust, Inc. is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality office properties primarily located in high-growth metropolitan areas across the United States. It serves corporate tenants across multiple industry sectors including technology, professional services, and healthcare, and pursues stable long-term returns for stakeholders via strategic property management and portfolio optimization.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
PDM vs TVTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $143.3M | $129.7M |
| Net Profit | $-45.0M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | — | -25.0% |
| Net Margin | -31.4% | — |
| Revenue YoY | 0.4% | 73.4% |
| Net Profit YoY | -27.9% | — |
| EPS (diluted) | $-0.10 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $143.3M | — | ||
| Q4 25 | $142.9M | $129.7M | ||
| Q3 25 | $139.2M | $164.9M | ||
| Q2 25 | $140.3M | $114.4M | ||
| Q1 25 | $142.7M | $81.7M | ||
| Q4 24 | $143.2M | $74.8M | ||
| Q3 24 | $139.3M | $62.9M | ||
| Q2 24 | $143.3M | $54.1M |
| Q1 26 | $-45.0M | — | ||
| Q4 25 | $-43.2M | — | ||
| Q3 25 | $-13.5M | $25.7M | ||
| Q2 25 | $-16.8M | $-12.8M | ||
| Q1 25 | $-10.1M | $-41.2M | ||
| Q4 24 | $-30.0M | — | ||
| Q3 24 | $-11.5M | $-54.8M | ||
| Q2 24 | $-9.8M | $-70.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | -25.0% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | -11.1% | ||
| Q1 25 | — | -52.2% | ||
| Q4 24 | — | -81.2% | ||
| Q3 24 | — | -89.3% | ||
| Q2 24 | — | -125.1% |
| Q1 26 | -31.4% | — | ||
| Q4 25 | -30.3% | — | ||
| Q3 25 | -9.7% | 15.6% | ||
| Q2 25 | -12.0% | -11.1% | ||
| Q1 25 | -7.1% | -50.4% | ||
| Q4 24 | -20.9% | — | ||
| Q3 24 | -8.3% | -87.1% | ||
| Q2 24 | -6.8% | -130.1% |
| Q1 26 | $-0.10 | — | ||
| Q4 25 | $-0.34 | $0.04 | ||
| Q3 25 | $-0.11 | $0.28 | ||
| Q2 25 | $-0.14 | $-0.14 | ||
| Q1 25 | $-0.08 | $-0.47 | ||
| Q4 24 | $-0.25 | $-0.71 | ||
| Q3 24 | $-0.09 | $-0.70 | ||
| Q2 24 | $-0.08 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.3M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.5B | $114.8M |
| Total Assets | $4.0B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.3M | — | ||
| Q4 25 | $731.0K | $93.0M | ||
| Q3 25 | $3.0M | $110.9M | ||
| Q2 25 | $3.3M | $75.2M | ||
| Q1 25 | $2.9M | $61.9M | ||
| Q4 24 | $109.6M | $58.5M | ||
| Q3 24 | $133.6M | $36.4M | ||
| Q2 24 | $138.5M | $32.3M |
| Q1 26 | — | — | ||
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — |
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.5B | $114.8M | ||
| Q3 25 | $1.5B | $73.6M | ||
| Q2 25 | $1.5B | $32.7M | ||
| Q1 25 | $1.6B | $32.8M | ||
| Q4 24 | $1.6B | $59.1M | ||
| Q3 24 | $1.6B | $-30.5M | ||
| Q2 24 | $1.7B | $15.1M |
| Q1 26 | $4.0B | — | ||
| Q4 25 | $4.0B | $605.2M | ||
| Q3 25 | $4.0B | $538.6M | ||
| Q2 25 | $4.0B | $555.3M | ||
| Q1 25 | $4.0B | $548.8M | ||
| Q4 24 | $4.1B | $594.1M | ||
| Q3 24 | $4.1B | $504.4M | ||
| Q2 24 | $4.2B | $551.1M |
| Q1 26 | — | — | ||
| Q4 25 | 1.49× | — | ||
| Q3 25 | 1.43× | — | ||
| Q2 25 | 1.41× | — | ||
| Q1 25 | 1.40× | — | ||
| Q4 24 | 1.40× | — | ||
| Q3 24 | 1.36× | — | ||
| Q2 24 | 1.34× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 110.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.6M | $60.7M | ||
| Q3 25 | $35.8M | $14.3M | ||
| Q2 25 | $50.1M | $5.0M | ||
| Q1 25 | $3.7M | $-42.2M | ||
| Q4 24 | $198.1M | $-35.7M | ||
| Q3 24 | $42.9M | $-42.5M | ||
| Q2 24 | $66.8M | $-40.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-40.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -74.5% |
| Q1 26 | 110.3% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PDM
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
